Current research in otosclerosis

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 14, Issue 5, 2006, Pages 347-351

  Stankovic, Konstantina M ^b   McKenna, Michael J ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b NONE

Author keywords

Angiogenesis; Bone remodeling; Measles virus; Osteoprotegerin; Otosclerosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANGIOGENESIS; COCHLEA; DISEASE ASSOCIATION; DISEASE MODEL; ENDOCRINE SYSTEM; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MODEL; GENETIC PREDISPOSITION; HEARING LOSS; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; KNOCKOUT MOUSE; MEASLES; MEASLES VIRUS; MOLECULAR MECHANICS; NONHUMAN; OTOSCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; REVIEW; SOFT TISSUE; TEMPORAL BONE; TREATMENT PLANNING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BONE REMODELING; ENDOCRINE SYSTEM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEASLES VIRUS; MICE; OSTEOPROTEGERIN; OTOSCLEROSIS; RESEARCH; TEMPORAL BONE;

EID: 33748769260     PISSN: 10689508     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moo.0000244194.97301.19     Document Type: Review

References (61)

1. Morrison AW. Genetic factors in otosclerosis. Ann R Coll Surg Engl 1967; 41:202-237.
2. Altmann F, Glasgold A, Macduff JP. The incidence of otosclerosis as related to race and sex. Ann Otol Rhinol Laryngol 1967; 76:377-392.
3. Chole RA, McKenna M. Pathophysiology of otosclerosis. Otol Neurotol 2001; 22:249-257.
4. Wang PC, Merchant SN, McKenna MJ, et al. Does otosclerosis occur only in the temporal bone? Am J Otol 1999; 20:162-165.
5. Frisch T, Sorensen MS, Overgaard S, Bretlau P. Estimation of volume referent bone turnover in the otic capsule after sequential point labeling. Ann Otol Rhinol Laryngol 2000; 109:33-39.
6. Frisch T, Sorensen MS, Overgaard S, Bretlau P. Predilection of otosclerotic foci related to the bone turnover in the otic capsule. Acta Otolaryngol Suppl 2000; 543:111-113.
7. Menger DJ, Tange RA. The aetiology of otosclerosis: a review of the literature. Clin Otolaryngol Allied Sci 2003; 28:112-120.
8. Larson A. Otosclerosis: a genetic and clinical study. Acta Otolaryngol 1960; 154:1-86.
9. Causse JR, Causse JB. Otospongiosis as a genetic disease Early detection, medical management, and prevention. Am J Otol 1984; 5:211-223.
10. Tomek MS, Brown MR, Mani SR, et al. Localization of a gene for otosclerosis to chromosome 15q25-q26. Hum Mol Genet 1998; 7:285-290.
11. Van Den Bogaert K, Govaerts PJ, Schatteman I, et al. A second gene for otosclerosis, OTSC2, maps to chromosome 7q34-36. Am J Hum Genet 2001; 68:495-500.
12. Chen W, Campbell CA, Green GE, et al. Linkage of otosclerosis to a third locus (OTSC3) on human chromosome 6p21.3-22.3. J Med Genet 2002; 39:473-477.
13. Brownstein Z, Goldfarb A, Levi H, et al. Chromosomal mapping and phenotypic characterization of hereditary otosclerosis linked to the OTSC4 locus. Arch Otolaryngol Head Neck Surg 2006; 132:416-424. The fourth locus of otosclerosis, OTSC4, was linked to the 16q21-23.2 interval, which includes several genes involved in the immune system and bone homeostasis.
14. Van Den Bogaert K, De Leenheer EMR, Chen W, et al. A fifth locus for otosclerosis, OTSC5, maps to chromosome 3q22-24. J Med Genet 2004; 41:450-453.
15. Iliadou V, Van Den Bogaert K, Eleftheriades N, et al. Monogenic nonsyndromic otosclerosis: audiological and linkage analysis in a large Greek pedigree. Int J Pediatr Otorhinolaryngol 2006; 70:631-637. The authors used linkage analysis in a large Greek pedigree segregating otosclerosis as a monogenic autosomal dominant trait, and excluded linkage to four known otosclerosis loci (OTSC1, OTSC2, OTSC3, and OTSC5), as well as to the COL1A1 and COL1A2 genes, indicating that otosclerosis involves at least five different genes.
16. McKenna MJ, Kristiansen AG, Tropitzsch AS. Similar COL1A1 expression in fibroblasts from some patients with clinical otosclerosis and those with type I osteogenesis imperfecta. Ann Otol Rhinol Laryngol 2002; 111:184-189.
17. McKenna MJ, Kristiansen AG, Bartley ML, et al. Association of COL1A1 and otosclerosis: evidence for a shared genetic etiology with mild osteogenesis imperfecta. Am J Otol 1998; 19:604-610.
18. McKenna MJ, Nguyen-Huynh AT, Kristiansen AG. Association of otosclerosis with Sp1 binding site polymorphism in COL1A1 gene: evidence for a shared genetic etiology with osteoporosis. Otol Neurotol 2004; 25:447-450.
19. Clayton AE, Mikulec AA, Mikulec KH, et al. Association between osteoporosis and otosclerosis in women. J Laryngol Otol 2004; 118:617-621.
20. Nager GT. Osteogenesis imperfecta of the temporal bone and its relation to otosclerosis. Ann Otol Rhinol Laryngol 1988; 97:585-593.
21. Pedersen U, Melsen F, Elbrond O, Charles P. Histopathology of the stapes in osteogenesis imperfecta. J Laryngol Otol 1985; 99:451-458.
22. McKenna MJ, Kristiansen AG, Bartley ML, et al. Association of COL1A1 and otosclerosis: evidence for a shared genetic etiology with mild osteogenesis imperfecta. Am J Otol 1998; 19:604-610.
23. McKenna MJ, Kristiansen AG, Tropitzsch AS. Similar COL1A1 expression in fibroblasts from some patients with clinical otosclerosis and those with type I osteogenesis imperfecta. Ann Otol Rhinol Laryngol 2002; 111:184-189.
24. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 2001; 7:613-635.
25. Rosa-Ranal M, de la Cruz DA, Lorena-Rubio Y, Larrea F. New paradigms in the regulation of bone metabolism. Rev Invest Clin 2001; 53:362-369.
26. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
27. Nakamura M, Udagawa N, Nakamura H. Bone remodeling and mineral homeostasis. Clin Calcium 2006; 16:46-53.
28. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001; 92:460-470.
29. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule. Laryngoscope 2005; 115:172-177. Researchers demonstrate that osteoprotegerin is expressed at high levels within the soft tissues of the cochlea and is secreted into the perilymph and the surrounding bone, and may serve to inhibit active bone remodeling within the otic capsule, especially adjacent to the cochlea. This paper describes for the first time the extensive system of interconnected canaliculi within the otic capsule with openings into perilymph, thus providing a possible anatomic route through which the cochlear soft tissue may control the surrounding otic capsule.
30. Zehnder AF, Kristiansen AG, Adams JC, et al. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. Laryngoscope 2005; 116:201-206. The investigators demonstrate that osteoprotegrin knockout mice provide the best available animal model to date to study abnormal otic capsule remodeling that closely resembles otosclerosis. Unlike human otosclerosis, however, these mice do not develop stapes fixation, and they exhibit diffuse remodeling affecting the ossicular chain and the systemic skeleton.
31. McKenna MJ, Mills BG, Galey FR, Linthicum FH Jr. Filamentous structures morphologically similar to viral nucleocapsids in otosclerotic lesions in two patients. Am J Otol 1986; 7:25-28.
32. McKenna MJ, Mills BG. Immunohistochemical evidence of measles virus antigens in active otosclerosis. Otolaryngol Head Neck Surg 1989; 101:415-421.
33. McKenna MJ, Kristiansen AG, Haines J. Polymerase chain reaction amplification of a measles virus sequence from human temporal bone sections with active otosclerosis. Am J Otol 1996; 17:827-830.
34. McKenna MJ, Mills BG. Ultrastructural and immunohistochemical evidence of measles virus in active otosclerosis. Acta Otolaryngol Suppl 1990; 470:130-139; discussion 139-140.
35. Niedermeyer HP, Arnold W. Otosclerosis: a measles virus associated inflammatory disease. Acta Otolaryngol 1995; 115:300-303.
36. Arnold W, Sedlmeier R, Wiest I, et al. Progress in basic research of otosclerosis. Otolaryngol Pol 2000; 54:281-283.
37. Karosi T, Konya J, Szabo LZ, Sziklai I. Measles virus prevalence in otosclerotic stapes footplate samples. Otol Neurotol 2004; 25:451-456.
38. Vrabec JT, Coker NJ. Stapes surgery in the United States. Otol Neurotol 2004; 25:465-469.
39. Niedermeyer HP, Arnold W, Schuster M, et al. Persistent measles virus infection and otosclerosis. Ann Otol Rhinol Laryngol 2001; 110:897-903.
40. Karosi T, Konya J, Petko M, et al. Two subgroups of stapes fixation: otosclerosis and pseudo-otosclerosis. Laryngoscope 2005; 115:1968-1973.
41. Arnold W, Niedermeyer HP, Lehn N, et al. Measles virus in otosclerosis and the specific immune response of the inner ear. Acta Otolaryngol 1996; 116:705-709.
42. Lolov SR, Encheva VI, Kyurkchiev SD, et al. Antimeasles immunoglobulin G in sera of patients with otosclerosis is lower than that in healthy people. Otol Neurotol 2001; 22:766-770.
43. Karosi T, Konya J, Petko M, et al. Antimeasles immunoglobulin g for serologic diagnosis of otosclerotic hearing loss. Laryngoscope 2006; 116:488-493. The authors demonstrate that a very specific and sensitive method for preoperative diagnosis of ossicular chain fixation due to otosclerosis is a combination of decreased level of antimeasles IgG serum and conductive hearing loss.
44. Lawrence DM, Patterson CE, Gales TL, et al. Measles virus spread between neurons requires cell contact but not CD46 expression, syncytium formation, or extracellular virus production. J Virol 2000; 74:1908-1918.
45. Raisz LG, Kream BE, Lorenzo JA. Metabolic bone disease. In: Williams RH, Larsen PR, Kronenberg HM, Polosky KS, editors. Williams textbook of endocrinology. Philadelphia: WB Saunders; 2002. pp. 1373-1410.
46. Gapany-Gapanavicius B. The incidence of otosclerosis in the general population. Isr J Med Sci 1975; 11:465-468.
47. Gristwood RE, Venables WN. Otosclerotic obliteration of oval window niche: an analysis of the results of surgery. J Laryngol Otol 1975; 89:1185-1217.
48. Lippy WH, Berenholz LP, Schuring AG, Burkey JM. Does pregnancy affect otosclerosis? Laryngoscope 2005; 115:1833-1836. The authors found no adverse effect on hearing in otosclerotic women who had children compared with women without children. Even with increasing numbers of pregnancies, no deleterious impact was noted.
49. Hultcrantz M, Simonoska R, Stenberg AE. Estrogen and hearing: a summary of recent investigations. Acta Otolaryngol 2006; 126:10-14.
50. Jensen KJ, Nielsen HE, Elbrond O, Hansen HH. Mineral content of skeletal bones in otosclerosis. Clin Otolaryngol Allied Sci 1979; 4:339-342.
51. Lolov SR, Edrev GE, Kyurkchiev SD, Kehayov IR. Elevated autoantibodies in sera from otosclerotic patients are related to the disease duration. Acta Otolaryngol 1998; 118:375-380.
52. Grayeli AB, Sterkers O, Roulleau P, et al. Parathyroid hormone-parathyroid hormone-related peptide receptor expression and function in otosclerosis. Am J Physiol 1999; 277 (6 Pt 1):E1005-E1012.
53. Nakashima T, Sone M, Fujii H, et al. Blood flow to the promontory in cochlear otosclerosis. Clin Otolaryngol 2006; 31:110-115. The authors measured blood flow to the promontory through the tympanic membrane using laser speckle flowgraphy and laser Doppler flowmetry and found that patients with otosclerosis and Schwartze sign exhibited elevated and pulsating blood flow to the promontory.
54. Jyung RW, Wacharasindhu C. Quantification of angiogenesis in otosclerosis. Laryngoscope 2005; 115:811-816. The authors distinguish clinical versus histologic otosclerosis based on significantly greater quantitative measures of angiogenesis in clinical otosclerosis, suggesting that sustained angiogenesis may be a determinant of clinical disease.
55. Yoo TJ, Stuart JM, Kang AH, et al. Type II collagen autoimmunity in otosclerosis and Meniere's disease. Science 1982; 217:1153-1155.
56. Bujia J, Alsalameh S, Jerez R, et al. Antibodies to the minor cartilage collagen type IX in otosclerosis. Am J Otol 1994; 15:222-224.
57. Lolov SR, Edrev GE, Kyurkchiev SD, et al. Elevated autoantibodies in sera from otosclerotic patients are related to the disease duration. Acta Otolaryngol (Stockh) 1998; 118:375-380.
58. Sørensen MS, Nielsen LP, Bretlau P, et al. The role of type II collagen autoimmunity in otosclerosis revisited. Acta Otolaryngol 1988; 105:242-247.
59. Yoo TJ, Tomoda K, Stuarrt JM, et al. Type II collagen-induced autoimmune otospongiosis: a preliminary report. AnnOtol Rhinol Laryngol 1983; 92:103-108.
60. Harris JP, Woolf NK, Ryan AF. A reexamination of experimental type II collagen autoimmunity: middle and inner ear morphology and function. Ann Otol Rhinol Laryngol 1986; 95:176-180.
61. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24:33-63.